045024cb A620 4c5b A4eb 4b890f177b7f · 20 questions

AbbVie pledges $100 billion for tariff and pricing exemptions

Pharma giant negotiates tariff and price control exemptions with White House·January 12, 2026

AbbVie announced on Jan. 12, 2026, that it will invest $100 billion in U.S. research, development, and manufacturing over the next decade. The pharma giant also pledged to lower Medicaid drug prices and participate in Trump's direct-to-consumer TrumpRx platform with blockbuster drugs including Humira, Synthroid, Combigan, and Alphagan. In exchange, AbbVie secured exemptions from tariffs and all future federal drug pricing mandates for three years.

The deal marks the Trump administration's largest corporate commitment yet under its "most favored nation" program. Critics call it a pay-to-play scheme that lets pharma companies buy their way out of accountability. AbbVie spent $7 billion annually marketing Humira before its patent expired, and Medicare alone spent $7 billion per year on that one drug.

Key facts

AbbVie announced a $100 billion U.S. investment pledge on Jan. 12, 2026, spread over 10 years. The investment covers research, development, and capital expenditures including manufacturing facilities. It's the largest corporate commitment under Trump's 'most favored nation' pharma program.

In exchange for the investment, AbbVie secured a three-year exemption from all tariffs on pharmaceutical imports. The company also won exemptions from any future federal drug pricing mandates, including potential reforms to Medicare negotiations. The White House confirmed the exemptions but kept other deal terms confidential.

AbbVie pledged to lower Medicaid drug prices and join TrumpRx, a new direct-to-consumer government platform. The company will offer Humira, Synthroid, Combigan, and Alphagan through the program. Humira alone cost Medicare $7 billion annually before its biosimilar competition arrived in 2025.

Critics say the deal lets AbbVie pay to avoid accountability on drug pricing. Before Humira's patent expired, AbbVie spent $7 billion per year marketing the drug while raising prices repeatedly. The company fought to delay biosimilar competition through over 130 patents, a strategy called a 'patent thicket.'

The $100 billion pledge has no public enforcement mechanism or timeline verification. Similar deals with Eli Lilly, Merck, and other pharma giants also lack detailed terms or oversight. Industry analysts note these companies already planned major U.S. expansions before the deals were announced.

Trump has used these corporate announcements to claim he's lowering drug prices without legislation. Congress hasn't passed comprehensive drug pricing reform since the Inflation Reduction Act in 2022, which allowed limited Medicare negotiations. AbbVie's exemption from future mandates blocks potential reforms.

AbbVie employs 29,000 people in the U.S. and sells drugs to 16 million Americans annually. The company reported $54.3 billion in global revenue for 2024. CEO Robert Michael called the deal essential to 'protect U.S. pharmaceutical innovation' while maintaining pricing flexibility.